BioCryst Pharmaceuticals Inc BCRX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 31, 2024 (filed on Apr 02, 2024)

Insider Name:

Thackray Helen M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-7,525

Price:

$5.08
Feb 29, 2024 (filed on Mar 04, 2024)

Insider Name:

Milano Vincent

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

999

Price:

$5.63
Feb 29, 2024 (filed on Mar 04, 2024)

Insider Name:

Heggie Theresa

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

999

Price:

$5.63
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

10,000

Price:

--
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

10,000

Price:

--
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-20,000

Price:

--
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Thackray Helen M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,580

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Stonehouse Jon P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-14,089

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Gayer Charles K

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,482

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Doyle Anthony

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,482

Price:

$6.05

Filings by filing date

Mar 31, 2024 (filed on Apr 02, 2024)

Insider Name:

Thackray Helen M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-7,525

Price:

$5.08
Feb 29, 2024 (filed on Mar 04, 2024)

Insider Name:

Milano Vincent

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

999

Price:

$5.63
Feb 29, 2024 (filed on Mar 04, 2024)

Insider Name:

Heggie Theresa

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

999

Price:

$5.63
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

10,000

Price:

--
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

10,000

Price:

--
Jan 03, 2024 (filed on Jan 04, 2024)

Insider Name:

Stonehouse Jon P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

G - Gift

# or value acquired/disposed of:

-20,000

Price:

--
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Thackray Helen M.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-5,580

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Stonehouse Jon P

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-14,089

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Gayer Charles K

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,482

Price:

$6.05
Dec 19, 2023 (filed on Dec 20, 2023)

Insider Name:

Doyle Anthony

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,482

Price:

$6.05

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	4505 Emperor Blvd Ste 200 DURHAM NC 27703-8457
Tel:	1-919-8597910
Website:	https://www.biocryst.com
IR:	See website

Key People

Jon P. Stonehouse President, Chief Executive Officer, Director	Anthony J. Doyle Chief Financial Officer	Charles K. Gayer Chief Commercial Officer
Helen M. Thackray Chief Research & Development Officer	Alane P. Barnes Chief Legal Officer, Corporate Secretary

Business Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Financial Overview

For the fiscal year ended 31 December 2023, BioCryst Pharmaceuticals Inc revenues increased 22% to $331.4M. Net loss decreased 8% to $226.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development Expense decrease of 19% to $185.6M (expense), Interest and other income increase from $5.1M to $15.8M (income).

Employees:	536 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,434M as of Dec 31, 2023
Annual revenue (TTM):	$331.41M as of Dec 31, 2023
EBITDA (TTM):	-$102.05M as of Dec 31, 2023
Net annual income (TTM):	-$226.54M as of Dec 31, 2023
Free cash flow (TTM):	-$97.31M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$450.28M as of Dec 31, 2023
Shares outstanding:	206,149,929 as of Feb 23, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization